AQST stock news · Aquestive Therapeutics, Inc.
Get alerts for AQST
Follow Aquestive Therapeutics, Inc. (AQST) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AQSTAquestive Therapeutics, Inc. says the FDA accepted its new application for Anaphylm™, with a decision expected by March 16, 2027.
Good for AQSTAquestive said the FDA accepted Anaphylm's resubmitted application for review and set a decision date. This is favorable progress, but approval is still pending.
Aquestive Therapeutics, Inc. has made a big deal with Eton Pharmaceuticals to sell LIBERVANT for seizures in the U.S.
Good for AQSTAquestive gave Eton exclusive U.S. rights to sell LIBERVANT, gaining an upfront fee, possible milestone payments, royalties, and supply income. This supports Aquestive, but sales depend on approvals.
Eton Pharmaceuticals has signed a big deal to sell LIBERVANT® in the U.S.
Good for AQSTAquestive receives an upfront fee, possible milestone payments, and sales royalties, and remains the exclusive supplier. Giving up U.S. sales rights is a cost, but these payments and the initial 20-year supply term support its business.
Aquestive Therapeutics, Inc. announced changes in its leadership, including new directors and officer appointments.
NeutralAQST adds an independent director to its 8-member board, with 57,000 stock options as compensation. The filing reports no change to its business or results, so its outlook is unchanged.
Aquestive Therapeutics, Inc. shares news about an upcoming meeting with investors.
NeutralAquestive filed an 8-K with an investor presentation; the disclosure is routine and does not change the company's outlook.
Aquestive gears up for FDA resubmission of severe allergy therapy after favorable study results.
Good for AQSTAquestive Therapeutics has announced positive findings from studies that support its upcoming FDA resubmission for a treatment for severe allergies, which is expected to enhance its market position and stock performance. The improvements in product usability and pharmacokinetic results are likely to bolster investor confidence and drive the stock price higher.